Khaitan Chemicals Q3 FY25 Results: Revenue jumps 56.02% to rS 198.76 crore, Net Profit at Rs 12.55 crore

Khaitan Chemicals and Fertilizers Limited announced its financial results for the third quarter ended December 31, 2024. The company showcased a mixed performance with a significant rise in revenue but continued losses compared to the same quarter last year.

Key Highlights:

Advertisement

Revenue from Operations: The company reported revenue of ₹198.76 crore in Q3 FY25, marking a 13.68% decrease QoQ from ₹230.64 crore in Q2 FY25. However, revenue surged by 56.02% YoY compared to ₹127.39 crore in Q3 FY24.

  • Q3 FY25: ₹198.76 crore
  • Q2 FY25: ₹230.64 crore
  • Q3 FY24: ₹127.39 crore
  • QoQ Change: -13.68%
  • YoY Change: +56.02%

Total Income: Total income stood at ₹199.87 crore, reflecting a 13.96% QoQ drop from ₹230.94 crore in Q2 FY25 but an 55.84% increase YoY compared to ₹128.30 crore in Q3 FY24.

  • Q3 FY25: ₹199.87 crore
  • Q2 FY25: ₹230.94 crore
  • Q3 FY24: ₹128.30 crore
  • QoQ Change: -13.96%
  • YoY Change: +55.84%

Net Profit/Loss: Khaitan Chemicals reported a net profit of ₹12.55 crore for Q3 FY25, a turnaround from a loss of ₹(3.07) crore QoQ and ₹(26.96) crore YoY in Q3 FY24.

  • Q3 FY25: ₹12.55 crore
  • Q2 FY25: ₹(3.07) crore
  • Q3 FY24: ₹(26.96) crore
  • QoQ Change: Turnaround
  • YoY Change: Turnaround

Expenses: Total expenses for the quarter were ₹198.01 crore, reflecting a 14.20% decrease QoQ from ₹230.73 crore but a 29.06% increase YoY from ₹153.52 crore.

  • Q3 FY25: ₹198.01 crore
  • Q2 FY25: ₹230.73 crore
  • Q3 FY24: ₹153.52 crore
  • QoQ Change: -14.20%
  • YoY Change: +29.06%

Khaitan Chemicals’ mixed performance highlights the company’s ongoing challenges with costs, even as revenues saw a notable increase YoY. Investors will be keen to observe future quarters for sustained profitability and operational efficiency.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions.